新鲜囊胚移植中hCG触发和标准黄体支持后,取卵后第3天至第5天血清孕酮下降与持续妊娠率降低相关
该前瞻性队列研究纳入340例新鲜囊胚移植患者,采用hCG触发和标准黄体支持,测量取卵后多个时间点血清孕酮。约三分之一患者取卵后第3天至第5天孕酮下降,其持续妊娠率显著低于孕酮上升者(33.6% vs 49.1%,OR 0.53,95%CI 0.33-0.84,P=0.008)。
要点
- 取卵后第3天至第5天血清孕酮下降见于约三分之一患者,与持续妊娠率降低约2倍相关。
- 孕酮下降组持续妊娠率33.6%,孕酮上升组49.1%,OR 0.53(95%CI 0.33-0.84,P=0.008)。
- BMI是孕酮下降的唯一显著预测因素(OR 1.128,95%CI 1.064-1.197),BMI越高风险越高。
核心结论
- 取卵后第3天至第5天血清孕酮下降与新鲜囊胚移植持续妊娠率降低约2倍相关。
- 约三分之一患者出现孕酮下降,可能通过两次孕酮测量识别。
研究设计与样本
- 前瞻性队列研究,初始连续入组558例患者,340例符合纳入排除标准并纳入最终分析。
- 纳入标准:女性年龄≤40岁、BMI≤35 kg/m2、获取≥3枚卵母细胞、使用GnRH激动剂或拮抗剂方案联合重组hCG 6500 IU触发、标准黄体支持、新鲜囊胚移植。
- 排除标准:GnRH激动剂或双触发、触发日血清孕酮>1.5 ng/ml、卵裂期胚胎移植。
- 黄体支持为阴道孕酮凝胶(Crinone,90 mg,8%,Merck)每日一次。
- 在触发日、取卵日、取卵后第3天、第5天和第14天测量血清孕酮,采血时间标准化为早晨阴道孕酮凝胶给药后3-5小时。
主要发现
- 触发日、取卵日、取卵后第3天、第5天和第14天孕酮中位数(最小值-最大值)分别为0.83 ng/ml(0.18-1.42)、5.81 ng/ml(0.80-22.72)、80.00 ng/ml(22.91-161.05)、85.91 ng/ml(15.66-171.78)和13.46 ng/ml(0.18-185.00)。
- 取卵后第3天至第5天,116例(34.1%)患者孕酮下降(负ΔP4),220例(64.7%)患者孕酮上升(正ΔP4)。
- 负ΔP4组取卵后第5天孕酮为69.67 ng/ml(15.66-150.02),显著低于正ΔP4组的100.51 ng/ml(26.41-171.78)(P<0.001);取卵后第14天分别为8.28 ng/ml(0.28-157.00)和19.01 ng/ml(0.18-185.00)(P<0.001)。
- 负ΔP4组持续妊娠率为33.6%,正ΔP4组为49.1%,OR 0.53(95%CI 0.33-0.84,P=0.008);该降低源于初始妊娠率较低而非总体流产率增加。
- 负ΔP4患者中,ΔP4幅度是持续妊娠的显著预测因素(调整AUC=0.65,95%CI 0.59-0.71),最佳阈值为-8.73 ng/ml,敏感度和特异度分别为48.7%和79.2%。
关键数值与推荐
- 负ΔP4定义为取卵后第5天血清孕酮低于取卵后第3天。
- 持续妊娠定义为妊娠≥12周。
- 刺激方案:GnRH激动剂方案53例,GnRH拮抗剂方案287例。
临床怎么用
- 作者认为,取卵后第3天和第5天两次血清孕酮测量可识别约三分之一孕酮下降且持续妊娠率降低约2倍的患者。
- 作者建议,通过额外孕酮补充挽救这些IVF周期或采用囊胚全冷冻策略应在未来随机对照试验中检验。
局限性
- 黄体中期孕酮的生理性昼夜脉冲分泌是局限性,但采血时间已标准化以减少影响。
- 作者建议额外孕酮补充或囊胚全冷冻策略需在未来随机对照试验中检验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Do early- and mid-luteal serum progesterone (P4) levels impact ongoing pregnancy rates (OPRs) in fresh blastocyst transfer cycles using standard luteal phase support (LPS)? SUMMARY ANSWER: A drop in serum P4 level from oocyte pick-up (OPU) + 3 days to OPU + 5 days (negative ΔP4) is associated with a ∼2-fold decrease in OPRs. WHAT IS KNOWN ALREADY: In fresh embryo transfer cycles, significant inter-individual variation occurs in serum P4 levels during the luteal phase, possibly due to differences in endogenous P4 production after hCG trigger and/or differences in bioavailability of exogenously administered progesterone (P) via different routes. Although exogenous P may alleviate this drop in serum P4 in fresh transfer cycles, there is a paucity of data exploring the possible impact on reproductive outcomes of a reduction in serum P4 levels. STUDY DESIGN, SIZE, DURATION: Using a prospective cohort study design, following the initial enrollment of 558 consecutive patients, 340 fulfilled the inclusion and exclusion criteria and were included in the final analysis. The inclusion criteria were: (i) female age ≤40 years, (ii) BMI ≤35 kg/m2, (iii) retrieval of ≥3 oocytes irrespective of ovarian reserve, (iv) the use of a GnRH-agonist or GnRH-antagonist protocol with recombinant hCG triggering (6500 IU), (v) standard LPS and (vi) fresh blastocyst transfer. The exclusion criteria were: (i) triggering with GnRH-agonist or GnRH-agonist plus recombinant hCG (dual trigger), (ii) circulating P4 >1.5 ng/ml on the day of trigger and (iii) cleavage stage embryo transfer. Each patient was included only once. The primary outcome was ongoing pregnancy (OP), as defined by pregnancy ≥12 weeks of gestational age. PARTICIPANTS/MATERIALS, SETTING, METHODS: A GnRH-agonist (n = 53) or GnRH-antagonist (n = 287) protocol was used for ovarian stimulation. Vaginal progesterone gel (Crinone, 90 mg, 8%, Merck) once daily was used for LPS. Serum P4 levels were measured in all patients on five occasions: on the day of ovulation trigger, the day of OPU, OPU + 3 days, OPU + 5 days and OPU + 14 days; timing of blood sampling was standardized to be 3-5 h after the morning administration of vaginal progesterone gel. The delta P4 (ΔP4) level was calculated by subtracting the P4 level on the OPU + 3 days from the P4 level on the OPU + 5 days, resulting in either a positive or negative ΔP4. MAIN RESULTS AND THE ROLE OF CHANCE: The median P4 (min-max) on the day of triggering, day of OPU, OPU + 3 days, OPU + 5 days and OPU + 14 days were 0.83 ng/ml (0.18-1.42), 5.81 ng/ml (0.80-22.72), 80.00 ng/ml (22.91-161.05), 85.91 ng/ml (15.66-171.78) and 13.46 ng/ml (0.18-185.00), respectively. Serum P4 levels uniformly increased from the day of OPU to OPU + 3 days in all patients; however, from OPU + 3 days to OPU + 5 days, some patients had a decrease (negative ΔP4; n = 116; 34.1%), whereas others had an increase (positive ΔP4; n = 220; 64.7%), in circulating P4 levels. Although the median (min-max) P4 levels on the day of triggering, the day of OPU, and OPU + 3 days were comparable between the negative ΔP4 and positive ΔP4 groups, patients in the former group had significantly lower P4 levels on OPU + 5 days [69.67 ng/ml (15.66-150.02) versus 100.51 ng/ml (26.41-171.78); P < 0.001] and OPU + 14 days [8.28 ng/ml (0.28-157.00) versus 19.01 ng/ml (0.18-185.00), respectively; P < 0.001]. A drop in P4 level from OPU + 3 days to OPU + 5 days (negative ΔP4) was seen in approximately one-third of patients and was associated with a significantly lower OPR when compared with positive ΔP4 counterparts [33.6% versus 49.1%, odds ratio (OR); 0.53, 95% CI; 0.33-0.84; P = 0.008]; this decrease in OPR was due to lower initial pregnancy rates rather than increased overall pregnancy loss rates. For negative ΔP4 patients, the magnitude of ΔP4 was a significant predictor of OP (adjusted AUC = 0.65; 95% CI; 0.59-0.71), with an optimum threshold of -8.73 ng/ml, sensitivity and specificity were 48.7% and 79.2%, respectively. BMI (OR; 1.128, 95% CI; 1.064-1.197) was the only significant predictor of having a negative ΔP4; the higher the BMI, the higher the risk of having a negative ΔP4. Among positive ΔP4 patients, the magnitude of ΔP4 was a weak predictor of OP (AUC = 0.56, 95% CI; 0.48-0.64). Logistic regression analysis showed that blastocyst morphology (OR; 5.686, 95% CI; 1.433-22.565; P = 0.013) and ΔP4 (OR; 1.013, 95% CI; 0.1001-1.024; P = 0.031), but not the serum P4 level on OPU + 5 days, were the independent predictors of OP. LIMITATIONS, REASONS FOR CAUTION: The physiological circadian pulsatile secretion of P4 during the mid-luteal phase is a limitation; however, blood sampling was standardized to reduce the impact of timing. WIDER IMPLICATIONS OF THE FINDINGS: Two measurements (OPU + 3 days and OPU + 5 days) of serum P4 may identify those patients with a drop in P4 (approximately one-third of patients) associated with ∼2-fold lower OPRs. Rescuing these IVF cycles with additional P supplementation or adopting a blastocyst freeze-all policy should be tested in future randomized controlled trials. STUDY FUNDING/COMPETING INTEREST(S): None. S.C.E. declares receipt of unrestricted research grants from Merck and lecture fees from Merck and Med.E.A. P.H. has received unrestricted research grants from MSD and Merck, as well as honoraria for lectures from MSD, Merck, Gedeon-Richter, Theramex, and IBSA. H.Y. declares receipt of honorarium for lectures from Merck, IBSA and research grants from Merck and Ferring. The remaining authors declare that they have no conflict of interest. TRIAL REGISTRATION NUMBER: The study was registered at clinical trials.gov (NCT04128436).
引用
- Uyanik E, Mumusoglu S, Polat M, et al. A drop in serum progesterone from oocyte pick-up +3 days to +5 days in fresh blastocyst transfer, using hCG-trigger and standard luteal support, is associated with lower ongoing pregnancy rates. Hum Reprod. 2023. PMID: 36478179. doi:10.1093/humrep/deac255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。